feedback welcome

Fluvoxamine-agomelatine

From Psychiatrynet

(Difference between revisions)
Jump to:navigation, search
[draft revision][draft revision]
(geen newline/spaties voor ref)
Line 11: Line 11:
* If necessary, the dosage of agomelatine can be increased to 50 mg/day.
* If necessary, the dosage of agomelatine can be increased to 50 mg/day.
| info =  
| info =  
-
* Fluvoxamine stops the metabolism of agomelatine via CYP1A2 (90%) and via CYP2C9/2C19 (10%).
+
* Fluvoxamine stops the metabolism of agomelatine via CYP1A2 (90%) and via CYP2C9/2C19 (10%).<ref name="agoswitch"> {{Pubmed|20196187|McAllister-Williams RH et al. The use of antidepressants in clinical practice: focus on agomelatine. Hum Psychopharmacol. 2010 Mar 1;25(2):95-102}}</ref>
-
<ref name="agoswitch"> {{Pubmed|20196187|McAllister-Williams RH et al. The use of antidepressants in clinical practice: focus on agomelatine. Hum Psychopharmacol. 2010 Mar 1;25(2):95-102}}</ref>
+
}}
}}

Revision as of 10:29, 5 March 2010

Fluvoxamine
Type Antidepressant
Group SSRI
links
Medscape Fluvoxamine
PubChem 5324346
PubMed Fluvoxamine
Kompas (Dutch) Fluvoxamine
Wikipedia Fluvoxamine
Agomelatine
Type Antidepressant
Group other
links
ATC-code N06AX22
EMEA valdoxan
PubChem 82148
PubMed Agomelatine
Kompas (Dutch) Agomelatine
Wikipedia Agomelatine

Switch medication from fluvoxamine to agomelatine.

Nietinrijdenbord.png Stop fluvoxamine
Eenrichtingbord.png Start agomelatine
Infobord.png More information
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.
Navigation
About